![](https://www.diabetesnews.com/wp-content/uploads/2013/01/depositphotos_2893773-Human-kidneys-150x150.jpg)
Many patients with chronic kidney disease are at a higher risk for severe kidney and heart health issues. The DAPA-CKD trial was designed to see the impact of Dapagliflozin Propanediol, which is sold under the brand name Farxiga, in patients with and without type 2 diabetes who had chronic kidney disease. Read more